ClinicalTrials.gg
RecruitingNCT07316062MAPUpdated Oct 21, 2026

A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China

An observational study in Non-Small-Cell Lung, sponsored by AstraZeneca. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by AstraZeneca · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
3,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 210 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca — 26 open to participants now, 79 under way, 28 of them phase 3. Carcinoma, Non-Small-Cell Lung · AstraZeneca.

Planned enrollment
4th of 67
3,000 · median 350
Started
2026
with 8 others
Observational
67 of 210
10 open now
Primary completion
2029-04
later than 62 of 78 live
Registered
203rd of 210
by date

Among the 210 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, this one is the 4th largest by planned enrollment of the 67 observational ones that give a count, is one of 9 that started in 2026, is one of 67 observational ones, reaches primary completion later than 62 of the 78 other live ones, and was the 203rd registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

26 of the 210 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

20 more — sign in →

By country, each count listing its studies:

All 26 open studies →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 210 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, or all of them as a file.
02

Study summary

This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.

Read the detailed description

The primary objective of this study is to understand the evolution of initial treatment patterns among patients with early-stage (I-III) NSCLC.

03

Conditions studied

  • Non-Small-Cell Lung

Keywords

  • NSCLC, chart review
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The target population for this study will be patients diagnosed with stage I-III NSCLC treated in routine clinical practice with various treatment regimens (e.g., definitive treatment with surgery or radiotherapy, neoadjuvant, adjuvant and perioperative systemic therapies) who meet the study eligibility criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stage I-III at initial NSCLC diagnosis
  • Aged ≥18 years at first diagnosis of NSCLC
  • Timeframe of NSCLC diagnosis:

For DE1: diagnosed with NSCLC during the period between May 1st 2025 and December 31st 2025 For DE2: diagnosed with NSCLC during the period between May 1st 2026 and December 31st 2026 For DE3: diagnosed with NSCLC during the period between May 1st 2027 and December 31st 2027

Exclusion criteria

Exclusion Criteria:

  • NSCLC is not the primary cancer diagnosis
  • Patients with a recent history of other tumor or concurrent other tumor
  • Patients participating in interventional clinical trials at time of initial diagnosis
  • Patients with positive pregnancy status at the time of diagnosis
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
3,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Treatment Patterns

    Proportion of patients with different treatment regimens

    Time frame: Up to 50 months

  2. Proportion of unresected patients in SI/II/III

    Proportion of patients who are unresected among SI/II/III NSCLC patients enrolled, respectively

    Time frame: Up to 50 months

  3. CRT rate in USIII

    Proportion of patients who have CRT regimen among unresected SIII patients enrolled

    Time frame: Up to 50 months

Secondary outcomes

  1. Treatment Duration

    TKI treatment duration and discontinuation reason in EGFRm patients * Duration of treatment * Treatment discontinuation (time to discontinuation, and reason for discontinuation)

    Time frame: Up to 50 months

  2. Patterns of recurrence

    Type of recurrence following initial treatment regimen (Loco-regional recurrence, distant recurrence, other)

    Time frame: Up to 50 months

  3. Guideline adoption rate

    Resected EGFRm Stage IB-III * Proportion of patients received guideline recommended TKI adjuvant regimen among a. resected EGFRm Stage IB-III patients; b. patients with TKI adjuvant therapy Unresected Stage III * Proportion of patients received guideline recommended systemic IO and TKI regimens among patients who received CRT

    Time frame: Up to 50 months

07

Study locations

1 of 1 sites recruiting
  • Research Site
    Beijing, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified investigators can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Apr 2029, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2025
First posted
Jan 5, 2026
StartActual
Apr 29, 2026
Primary completionEst.
Apr 30, 2029
CompletionEst.
Apr 30, 2029
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07316062
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 5, 2026
Start date
Apr 29, 2026
Primary completion
Apr 30, 2029 (estimated)
Completion
Apr 30, 2029 (estimated)
Last update
Oct 21, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion